Progress in the clinical application and correlation between glucose transporter-1 and 18F-FDG PET/CT imaging for non-small cell lung cancer

非小细胞肺癌患者早期症状不明显，且 5 年生存率较低，因此早期诊治具有重要意义。葡萄糖转运蛋白 1（Glut-1）是人体内各组织细胞中最广泛分布的葡萄糖转运体，其在非小细胞肺癌中的表达与非小细胞肺癌的组织学类型、淋巴结转移、分化程度、恶化进程及预后有着密切联系。18-氟脱氧葡萄糖正电子发射计算机断层显像/计算机断层扫描（ 18F-FDG PET/CT）是基于恶性肿瘤葡萄糖代谢特点的分子影像学诊断方法，已广泛用于癌症的诊断、分期、疗效观察和预后评估。葡萄糖转运蛋白 1 受多种因素调控和影响，与 18F-FDG PET/CT 显像有着密切关系。现就葡萄糖转运蛋白 1 与非小细胞肺癌 18F-FDG PET/CT 显像的相关性研究与应用进展做简要综述，以期提高肺癌的诊治效能。.; Because of the unobvious early symptoms and low 5-year survival rate, the early diagnosis and treatment is of great significance for patients with non-small cell lung cancer. Glucose transporter-1 is the most widely distributed glucose transporters in various tissue cells in the human body, whose expression in non-small cell lung cancer is closely related to the histological types, lymph node metastasis, degree of differentiation, progression and prognosis. 18F-FDG PET/CT imaging, a molecular imaging diagnostic method, is based on the characteristics of glucose metabolism in malignant tumors, which has been widely applied in the cancer diagnosis, stage division, evaluation of therapeutic effects and prognosis evaluation. Glucose transporter-1 is regulated and influenced by many factors, and it is closely related to 18F-FDG PET/CT imaging. This article briefly reviews the progress in the clinical application and correlation between glucose transporter-1 and 18F-FDG PET/CT imaging for non-small cell lung cancer, in order to improve the diagnosis and treatment of lung cancer.